F573 / Gyre Therapeutics - LARVOL DELTA

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) - "Pipeline Development Updates:...F573: F573 is a caspase inhibitor and a potential Category 1 new drug for the treatment of acute/acute on-chronic liver failure ('ALF/ACLF'). Completion of the Phase 2 clinical trial of F573 as a treatment for ALF/ACLF is expected by the end of 2026."

Trial completion date • Liver Failure

Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). (ASCO-GU 2017) - P2; " A total of 573 patients were identified, 261 patients in SI, 201 patients in SS, and 111 patients in PS. Significant improvement in OS and TTF is seen using an individualized approach to mRCC patients, further supporting the growing body of evidence endorsing this practice. Further prospective validation awaits from the NCT01499121 study."

Clinical • Biosimilar • Oncology • Renal Cell Carcinoma

Long-Term Vascular Response to Cobalt-Chromium Everolimus-Eluting Stent: Five-Year Follow-Up Optical Coherence Tomography Study (AHA 2016) - " A total of 5738 struts in 35 CoCr-EESs were analyzed. CoCr-EES shows an excellent vascular response at 5-year follow-up. The lesion complexity might have little influence on long-term vascular response to CoCr-EES in stable patients."

Clinical • Biosimilar • Ophthalmology

Engraftment Site and Effectiveness of the Pan-Caspase Inhibitor F573 to Improve Engraftment in Mouse and Human Islet Transplantation in Mice. (PubMed) - "The pan-caspase inhibitor F573 markedly reduces human and mouse islet apoptosis and improves engraftment most effectively in the portal and DL subcutaneous sites."

Journal • Biosimilar • Diabetes • Metabolic Disorders

Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology. (PubMed) - J Clin Oncol - "Dexrazoxane was cardioprotective and did not compromise antitumor efficacy, did not increase the frequencies of toxicities, and was not associated with a significant increase in second malignancies with this doxorubicin-containing chemotherapy regimen. We recommend dexrazoxane as a cardioprotectant for children and adolescents who have malignancies treated with anthracyclines."

Journal • Acute Lymphocytic Leukemia • Biosimilar • Hematological Malignancies • Immunology • Leukemia • Non-Hodgkin’s Lymphoma • Oncology

Genomic Resources for Water Yam (Dioscorea alata L.): Analyses of EST-Sequences, De Novo Sequencing and GBS Libraries. (PubMed) - "Genotyping by sequencing reads on these two genotypes also revealed 36,790 overlapping SNP positions that are distributed throughout the genome. Our efforts in using different approaches in generating genomic resources provides a non-biased glimpse into the publicly available EST-sequences, yam genome, and GBS profiles with affirmation that the genomic complexity can be methodically unraveled and constitute a critical foundation for future studies in linkage mapping, germplasm analysis, and predictive breeding."

Journal • Biosimilar

Differential nuclear ATRX expression in sarcomas. (PubMed) - "Nuclear ATRX loss, either complete or heterogeneous, is encountered in a considerable number of high-grade sarcomas with non-specific genetic alterations. A causal relationship with ALT might be indicated at least in cases with a complete nuclear ATRX loss."

Journal • Biosimilar • Oncology • Sarcoma • Uterine Cancer

Removal of the eye in a tertiary care center of China: a retrospective study on 573 cases in 20 years. (PubMed) - Int J Ophthalmol - "Ocular trauma, tumor and infections were great threats to eyeball preservation. Early and effective controlling of any original protopathies was vital. Generally evisceration presented more superior and safe outcomes than enucleation did. Visual conditions of the sufferers should be focused on."

Journal • Retrospective data • Biosimilar • Immunology • Inflammation • Oncology

Increasing the dose of television advertising in a national antismoking media campaign: results from a randomised field trial. (PubMed) - Tob Control - "The US 2013 Tips antismoking media campaign compared standard and higher doses by randomisation of local media markets. Results demonstrate the effectiveness of a higher dose for engaging non-smokers and further increasing quit attempts among smokers, especially African-Americans."

Journal • Biosimilar

Cost Effectiveness of Implementing Integrated Management of Neonatal and Childhood Illnesses Program in District Faridabad, India. (PubMed) - PLoS One - "IMNCI program in Indian context is very cost effective and should be scaled-up as a major child survival strategy."

Journal • Biosimilar

Prediction for success rate of shock wave lithotripsy using mean stone density-stone heterogeneity index ratio calculating Hounsfield unit on non-contrast computed tomography (EAU 2017) - "...The distribution of ureteral stone locations was comprised of 573 cases of upper ureter stones (81.9%), 48 cases of mid-ureter stones (6.9%), and 79 cases of lower ureter stones (11.2%)... MSL, MSD, SHI, and MSD-SHI were independent predictors of one-session success after SWL for ureteral calculi. MSD-SHI showed higher predictive value compared to MSD or MSL in patients with relatively large stone."

Biomarker • Clinical • Heterogeneity • Biosimilar • Multiple Sclerosis

Nurses' perceptions of their professional practice environment: a cross-sectional study. (PubMed) - "A supportive and enabling work environment promotes professional development and the safety and quality of health care. Addressing these factors is important in optimising work place environments."

Journal • Biosimilar

Pan-caspase inhibitor F573 mitigates liver ischemia reperfusion injury in a murine model. (PubMed, PLoS One) - "The administration of pan-caspase inhibitor F573 in a murine in vivo model likely mitigates liver IRI based on decreased markers of cellular injury, decreased evidence of apoptosis, and improved cytokine profiles. Anakinra with etanercept, and BMX-001 did not demonstrate convincing efficacy at reducing IRI in this model, and likely need further optimization. The positive findings set rational groundwork for future translational studies of applying F573 during normothermic ex situ liver perfusion, with the aim of improving the quality of marginal grafts."

Journal • Preclinical